About
198,700.00KRW+9100.00 +4.80%
Closed • Updated at 16:56 GMT+00:00Market Cap$27.62B
P/E Ratio34.51
Volume844.7K
Beta0.35
RSI52.57
Gross Margin58.99%
Celltrion, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 21 2026
Celltrion to present seven abstracts in inflammatory bowel disease (IBD) at 2026 Digestive Disease Week® (DDW)
Mar 16 2026
Celltrion announces U.S. availability of AVTOZMA® (tocilizumab-anoh) subcutaneous (SC) formulation
Mar 13 2026
Zymfentra (Celltrion) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
Jan 14 2026
Celltrion presents innovative drug pipeline and U.S. manufacturing and R&D expansion strategy at the 44th Annual J.P. Morgan Healthcare Conference
Jan 7 2026
Celltrion to present at the 44th Annual J.P. Morgan Healthcare Conference
Community Chat
Ask AI
Try asking
Google Übersetzer